Application of Biomarkers in the Development of Drugs Intended for the Treatment of Osteoarthritis OARSI FDA Osteoarthritis Biomarkers Working Group
暂无分享,去创建一个
A R Poole | D Heinegård | R. Moskowitz | J. Menetski | D. Heinegård | D. Eyre | L. Lohmander | M. Todman | Y. Henrotin | P. Garnero | V. Kraus | V B Kraus | L S Lohmander | B Burnett | J Coindreau | S Cottrell | D Eyre | M Gendreau | J Gardiner | P Garnero | J Hardin | Y Henrotin | A Ko | G Matthews | J Menetski | R Moskowitz | S Persiani | J-C Rousseau | M Todman | S. Cottrell | J. Hardin | A. Robin Poole | S. Persiani | J. Coindreau | J. Rousseau | J. Gardiner | G. Matthews | M. Gendreau | B. Burnett | A. Ko
[1] A. Poole,et al. Early rheumatoid-like lesions in rabbits injected with foreign serum: relationship to localization of immune complexes in the lining tissues of joints and cellular content of synovial fluid. , 1978, International archives of allergy and applied immunology.
[2] H. Roos,et al. Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis , 1997, Annals of the rheumatic diseases.
[3] A. Poole,et al. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. , 2004, Journal of immunological methods.
[4] Farshid Guilak,et al. Urea as a passive transport marker for arthritis biomarker studies. , 2002, Arthritis and rheumatism.
[5] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[6] H. Babich,et al. Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay , 1991, Applied and environmental microbiology.
[7] T. Kepler,et al. First Qualification Study of Serum Biomarkers as Indicators of Total Body Burden of Osteoarthritis , 2010, PloS one.
[8] S. Clarke,et al. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. , 2004, Arthritis and rheumatism.
[9] K. Brandt,et al. Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing. , 2007, Arthritis and rheumatism.
[10] A. Reiner,et al. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. , 2003, The Journal of rheumatology.
[11] D. Rennie,et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.
[12] L M Hinman,et al. The drug diagnostic co-development concept paper Commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop , 2006, The Pharmacogenomics Journal.
[13] K. Marshall,et al. Blood-based biomarkers for detecting mild osteoarthritis in the human knee. , 2005, Osteoarthritis and cartilage.
[14] J. Singer,et al. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. , 2005, The Journal of rheumatology.
[15] D. Heinegård,et al. Molecular markers of processes in cartilage in joint disease. , 1991, British journal of rheumatology.
[16] P. Qvist,et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. , 2001, Bone.
[17] Claus Christiansen,et al. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? , 2008, Pharmacological research.
[18] T. Spector,et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. , 2006, Arthritis and rheumatism.
[19] K. Brandt,et al. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. , 2006, The Journal of rheumatology.
[20] M. Percival,et al. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. , 2008, Osteoarthritis and cartilage.
[21] Claus Christiansen,et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. , 2006, Arthritis and rheumatism.
[22] R. Buck,et al. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. , 2006, Osteoarthritis and cartilage.
[23] K. Yoshida,et al. Analysis of unsaturated disaccharides from glycosaminoglycuronan by high-performance liquid chromatography. , 1989, Analytical biochemistry.
[24] B. Bresnihan,et al. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. , 2007, Arthritis and rheumatism.
[25] C. Bingham,et al. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. , 2006, Rheumatology.
[26] M. Kruhøffer,et al. Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. , 2007, The Journal of molecular diagnostics : JMD.
[27] H. Soares,et al. Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report , 2005, Pharmaceutical Research.
[28] D. Reid,et al. Clinical trials in rheumatoid arthritis and osteoarthritis , 2008 .
[29] M. Nevitt,et al. Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. , 1993, The Journal of rheumatology.
[30] Federico M Goodsaid,et al. Strategic paths for biomarker qualification. , 2008, Toxicology.
[31] A. Jaffe,et al. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. , 2008, Clinical chemistry.
[32] H. Hinghofer-Szalkay,et al. Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans , 1998, European Journal of Applied Physiology and Occupational Physiology.
[33] Jh. Kellgren. Radiological assessment of osteoarthrosis , 1957 .
[34] P. Tugwell,et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. , 1997, The Journal of rheumatology.
[35] P. Garnero,et al. PIIANP and HELIXII diurnal variation. , 2008, Osteoarthritis and cartilage.
[36] T. Spector,et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173] , 2005, Arthritis research & therapy.
[37] D J Hunter,et al. Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.
[38] O. Nemirovskiy,et al. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. , 2007, Analytical biochemistry.
[39] R. Coleman,et al. Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation. , 2009, Arthritis and rheumatism.
[40] J. Houwing-Duistermaat,et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study , 2005, Annals of the rheumatic diseases.
[41] P. Delmas,et al. Biological markers in osteoarthritis , 2007, Nature Clinical Practice Rheumatology.
[42] J. Wagner,et al. Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.
[43] A. Milewicz,et al. Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study. , 2008, Medical science monitor : international medical journal of experimental and clinical research.
[44] B. Mazières,et al. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study , 2007, Annals of the rheumatic diseases.
[45] D. Uebelhart,et al. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. , 1990, Bone and mineral.
[46] Alan Brett,et al. Trabecular morphometry by fractal signature analysis is a novel marker of osteoarthritis progression. , 2009, Arthritis and rheumatism.
[47] J. Singer,et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. , 2009, Arthritis and rheumatism.
[48] A. Cole,et al. Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints. , 2005, Arthritis and rheumatism.
[49] S. Christgau. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. , 2000, Clinical chemistry.
[50] W. Murphy,et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. , 1990, Arthritis and rheumatism.
[51] E. Losina,et al. Joint space narrowing and Kellgren-Lawrence progression in knee osteoarthritis: an analytic literature synthesis. , 2008, Osteoarthritis and cartilage.
[52] A. Poole,et al. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. , 1992, The Journal of clinical investigation.
[53] J. Tanus-Santos,et al. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. , 2005, Analytical biochemistry.
[54] S. Majumdar,et al. A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. , 2004, Magnetic resonance imaging.
[55] C. Helmick,et al. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. , 2003, Arthritis and rheumatism.
[56] L. Lesko,et al. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.
[57] Federico Goodsaid,et al. Process map proposal for the validation of genomic biomarkers. , 2006, Pharmacogenomics.
[58] Leonard Steinborn,et al. The United States Code of Federal Regulations 21 CFR, Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals , 2004 .
[59] P. Tugwell,et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. , 2007, The Journal of rheumatology.
[60] A. Sudo,et al. Changes in biochemical markers and prediction of effectiveness of intra-articular hyaluronan in patients with knee osteoarthritis. , 2008, Osteoarthritis and cartilage.
[61] Y. Henrotin,et al. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. , 2010, Osteoarthritis and cartilage.
[62] C. Christiansen,et al. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. , 2004, Arthritis and rheumatism.
[63] M. Hanes,et al. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. , 2002, Osteoarthritis and cartilage.
[64] H. Mischak,et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. , 2009, Journal of proteome research.
[65] F. Eckstein,et al. One year change of knee cartilage morphology in the first release of participants from the Osteoarthritis Initiative progression subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status , 2008, Annals of the rheumatic diseases.
[66] D. Eyre,et al. Biochemical Markers as Surrogate End Points of Joint Disease , 2008 .
[67] J. Jordan,et al. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. , 2006, Arthritis and rheumatism.
[68] P. Garnero,et al. Monitoring cartilage turnover , 2007, Current rheumatology reports.
[69] P. Dieppe,et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. , 1998, The Journal of clinical investigation.
[70] C. Rorabeck,et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. , 1994, The Journal of clinical investigation.
[71] F. Guilak,et al. Novel synovial fluid recovery method allows for quantification of a marker of arthritis in mice. , 2008, Osteoarthritis and Cartilage.
[72] V. Kraus,et al. Collagen Biomarkers for Arthritis Applications , 2006, Biomarker insights.
[73] Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels , 2009 .
[74] Nils Brünner,et al. Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers* , 2008, Molecular & Cellular Proteomics.
[75] D. Eyre,et al. Collagen cross-links as markers of bone and cartilage degradation , 2002 .
[76] D. Eyre,et al. The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. , 2009, Osteoarthritis and cartilage.
[77] E. Colman. The Food and Drug Administration's Osteoporosis Guidance Document: Past, Present, and Future , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[78] E. Thonar,et al. Accumulation of hyaluronate in human lung carcinoma as measured by a new hyaluronate ELISA. , 1989, Connective tissue research.
[79] Jean-Pierre Devogelaer,et al. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. , 2004, Osteoarthritis and cartilage.
[80] S. Miyauchi,et al. Quantitation of chondroitin 4-sulfate and chondroitin 6-sulfate in pathologic joint fluid. , 1992, Arthritis and rheumatism.
[81] W. Lems,et al. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. , 2010, Osteoarthritis and cartilage.
[82] D. Heinegård,et al. COMP Acts as a Catalyst in Collagen Fibrillogenesis* , 2007, Journal of Biological Chemistry.
[83] H C Charles,et al. Optimization of the fixed-flexion knee radiograph. , 2007, Osteoarthritis and cartilage.
[84] C. Christiansen,et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. , 2008, Osteoarthritis and cartilage.
[85] N. Bhardwaj,et al. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. , 1992, Arthritis and rheumatism.
[86] K. Brandt,et al. Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis , 2005, Annals of the rheumatic diseases.
[87] Mads Nielsen,et al. Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers , 2009, Arthritis research & therapy.
[88] P. Delmas,et al. Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. , 2001, Rheumatology.
[89] E. Thonar,et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. , 2006, Arthritis and rheumatism.
[90] M. Payton,et al. Soy protein may alleviate osteoarthritis symptoms. , 2004, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[91] D. Felson,et al. Whither osteoarthritis biomarkers? , 2009, Osteoarthritis and cartilage.
[92] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .
[93] P Kjaersgaard-Andersen,et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. , 2008, Osteoarthritis and cartilage.
[94] R. Moskowitz,et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.
[95] M. Dougados,et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. , 2002, Arthritis and rheumatism.
[96] T D Cooke,et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. , 1991, Arthritis and rheumatism.
[97] E. Thonar,et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. , 1985, The Journal of rheumatology.
[98] T. Cawston,et al. Markers of joint destruction: principles, problems, and potential , 2001, Annals of the rheumatic diseases.
[99] Y. Henrotin,et al. Type II collagen markers in osteoarthritis: what do they indicate? , 2007, Current opinion in rheumatology.
[100] J. Reginster,et al. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. , 2004, Clinical and experimental rheumatology.
[101] G. Embery,et al. Modulation of Collagen Fibrillogenesis by Dentinal Proteoglycans , 2005, Calcified Tissue International.
[102] E. Thonar,et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. , 1998, Osteoarthritis and cartilage.
[103] E. Roos,et al. Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis , 2006, BMC musculoskeletal disorders.
[104] P. Delmas,et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis , 2004, Annals of the rheumatic diseases.
[105] J B Renner,et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. , 1999, Arthritis and rheumatism.
[106] Staffan Larsson,et al. Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. , 2005, Arthritis and rheumatism.
[107] M. Karsdal,et al. Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[108] V. Kraus,et al. Variation in osteoarthritis biomarkers from activity not food consumption. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[109] Y. Washimi,et al. Content and sulfation pattern of keratan sulfate in hip osteoarthritis using high performance liquid chromatography. , 2000, The Journal of rheumatology.
[110] L. Sharma,et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. , 2007, Osteoarthritis and cartilage.
[111] V. Hascall,et al. The Many Faces of Osteoarthritis , 2002, Birkhäuser Basel.
[112] E. Thonar,et al. Effect of an exercise and dietary intervention on serum biomarkers in overweight and obese adults with osteoarthritis of the knee. , 2008, Osteoarthritis and cartilage.
[113] T. Spector,et al. Kellgren & Lawrence grade 1 osteophytes in the knee--doubtful or definite? , 2003, Osteoarthritis and cartilage.
[114] A Guermazi,et al. Change in joint space width: hyaline articular cartilage loss or alteration in meniscus? , 2006, Arthritis and rheumatism.
[115] C. Rorabeck,et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.
[116] V. Kraus,et al. Assessment of the utility of biomarkers of osteoarthritis in the guinea pig. , 2006, Osteoarthritis and cartilage.
[117] F. Frueh,et al. Biomarker qualification pilot process at the US Food and Drug Administration , 2007, The AAPS Journal.
[118] M. Dougados,et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. , 2004, Osteoarthritis and cartilage.
[119] E. Vignon,et al. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. , 2008, Clinical and experimental rheumatology.
[120] L. Ferrucci,et al. Serum protein signatures detect early radiographic osteoarthritis. , 2009, Osteoarthritis and cartilage.
[121] J. Kellgren,et al. Radiological Assessment of Osteo-Arthrosis , 1957, Annals of the rheumatic diseases.